Intravenous Iron Requirement in Adult Hemodialysis Patients
|
|
- Allen Alexander
- 5 years ago
- Views:
Transcription
1 Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct assistant professor at the Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey and Saint Peter s College, Jersey City, New Jersey. Objective. Chronic hemodialysis patients often require maintenance intravenous iron, as iron is an essential component of effective erythropoiesis. The Anemia Work Group (NKF-K/DOQI) anemia guidelines suggest a maintenance intravenous iron dose of mg, but the optimal maintenance dose regimen remains difficult to determine. K/DOQI recommends these iron parameters: TSAT 20% and <50%, ferritin 100 and <800 ng/ml. An assessment of the maintenance dose regimen used in the present study is presented in this article. Patients and Methods. Data were collected retrospectively to evaluate clinical response in 40 adult chronic hemodialysis patients who received regular maintenance intravenous iron sucrose of 100 mg either every other week or every fourth week based on their ferritin and transferrin saturation (TSAT) levels. If ferritin level was between 100 and 500 ng/ml and TSAT level was 20% and 30%, then iron sucrose was administered every other week; if ferritin was ng/ml or TSAT was 30% 45%, then iron sucrose was administered every fourth week. Ferritin and TSAT levels were monitored quarterly. Results. After the first quarter, 15 (38%) of the patients (n ¼ 15) remained on their original dosing regimen; 21 (53%) patients required adjustment to their regimen, either by discontinuing the regimen (n ¼ 18) or decreasing the dosing interval (n ¼ 3), 45% and 7.5% respectively; and 4 (10%) patients required additional intravenous iron supplementation. Conclusions. Iron sucrose administered at a dosage of 100 mg on a maintenance regimen either every other week or every fourth week exceeded most patients requirements. Maximum intravenous iron maintenance doses for adult chronic hemodialysis patients remain difficult to determine, and the maintenance iron requirement varies from patient to patient. Iron deficiency is common in patients undergoing hemodialysis (HD) treatment. When the kidneys fail, a patient will require either kidney transplantation or regular dialysis treatments to replace the functions normally performed by healthy kidneys. HD patients develop iron deficiency for a variety of reasons, including iron loss via dialysis-related procedures, bleeding from access sites, gastrointestinal bleeding, phlebotomies, erythropoietic therapy, and inadequate iron intake. 1 2 Because iron is essential for erythropoiesis, as iron stores deplete, anemia management of these patients becomes difficult. The Anemia Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) recommends regular maintenance intravenous (IV) iron therapy as part of anemia management of HD patients. 3 Iron deficiency is considered the most common cause of epoetin alfa resistance. Therefore, regular administration of iron is extremely important in anemia management. The K/DOQI guidelines recommend the administration of IV iron doses ranging from 25 to 125 mg and monitoring iron parameters regularly. It is also recommended that a transferrin saturation (TSAT) level of at least 20% but less than 50% and a ferritin level of ng/ml be achieved in order to maximize epoetin alfa therapy and to maintain a target hemoglobin level of g/dl. Optimal maintenance IV iron dosing of HD patients remains difficult to determine because the recommended ranges are broad. This article presents an assessment of the maintenance IV iron regimens for adult HD patients at the institution where the present study took place. Iron sucrose (100 mg) was administered every other week or every fourth week based on serum ferritin and transferrin saturation levels, and data were collected retrospectively to evaluate clinical responses. Patients and Methods Data were collected retrospectively during the second and third quarters of 2004 and into the first quarter of The process was approved by the institution s oversight committees, the nephrology department, the Pharmacy and Therapeutics Committee and the Medical Executive Committee. Patients receiving IV iron had to be at least 18 years old, receiving HD for SEPTEMBER 2006 DIALYSIS & TRANSPLANTATION 1
2 at least 1 year, receiving erythropoietic growth factor therapy to maintain target hemoglobin level (11 12 g/ dl), require IV iron supplementation, and have tolerated IV iron. The institution-approved protocol was for the administration of 100 mg of iron sucrose (Venofer, American Regent, Shirley, NY) IV push during HD treatment every other week (Group I, n ¼ 8) if ferritin was at least 100 but less than 500 ng/ml and TSAT was at least 20% but less than 30%, or every fourth week (Group II, n ¼ 32) if ferritin was ng/ ml or TSAT was 30% 45%. All orders had to be initiated by the physician. Iron indices (ferritin, iron, total iron building capacity, and TSAT) were monitored quarterly for 3 quarters. Regimen adjustment was as follows: if the iron parameters of those in Group I increased to the levels of those in Group II, dose interval was decreased from every other week to every fourth week; if the iron parameters of those in Group II fell to the levels of those in Group I, dose interval was increased from every fourth week to every other week; if TSAT was greater than 45% or ferritin was greater than 700 ng/ml, IV iron was discontinued. Analysis Success rates for the groups were analyzed. Standard error for Group I (every other week administration) was 18% (78% CI), and standard error for Group II (every fourth week administration) was 9% (91% CI). Variation between the 2 regimens was analyzed using Fisher s exact test. Armitage and Berry mid-p value ( ) was greater than 5%; therefore, there was no significant difference in the results between the regimens. Results After the first quarter, 25 of the 40 patients (62%) required regimen adjustments: 18 patients (45%) had their administration of IV iron discontinued, 3 patients (7.5%) had their dosing interval decreased, and 4 patients (10%) had their dosing interval increased. The remaining 15 patients (38%) did not require a change in therapy (Figure 1). Subanalysis of the every-otherweek and every-fourth-week regimens was follows. Originally, 8 patients were receiving the everyother-week regimen (Group I). After the first quarter, 75% of these patients required adjustments to their regimen: 3 patients (38%) had their administration of IV iron discontinued, 2 (25%) had their dosing interval decreased, and 1 (12%) had it increased. The remaining 2 patients (25%) maintained the same regimen (SE 18%, 78% CI) for the next 3 quarters. Of the 2 patients who required a decreased dosing interval after the first quarter, 1 required discontinuation after the second quarter, and the other patient remained on the same regimen for the entire evaluation (Table I). Originally, 32 patients received the every-fourth-week regimen (Group II). After the first quarter, 19 patients (59%) required a regimen adjustment: 15 patients (46.9%) had their administration of IV iron discontinued, 1 patient (3.1%) had the dosing interval decreased, and 3 patients (9.4%) had the dosing interval increased; the remaining 13 patients (40.6%) maintained the same regimen (SE 9%, 91% CI). By the end of the second quarter, 11 of the 32 patients in Group II (34.4%) remained on the same regimen, and 21 patients (65.6%) required a regimen adjustment: 17 (53%) had administration of IV iron discontinued, 1 (3%) had a decrease in the dosing interval, and 3 (10%) had an increased dosing interval. By the end of the third quarter, 10 of 32 patients (31.3%) remained on the same regimen, and 22 patients (68.8%) required a regimen adjustment: 18 patients (56%) had administration of IV iron discontinued, 1 (3%) had a decrease in the dosing interval, and 3 (10%) had an increase in the dosing interval (Table I). Discussion HD patients often require IV iron supplementation to maintain iron stores and to replace iron loss. Maintenance administration of IV iron in conjunction with erythropoietic agents is well recognized as a means to maintain effective erythropoiesis and to effectively manage anemia for patients undergoing HD treatment. 2 4 However, determining the most effective dose and the frequency of administration of IV iron to these patients to replace iron loss and maintain adequate iron stores can be a challenge. Maintenance doses have been reported anywhere from a 25 mg to 125 mg administered with varied frequencies. IV administration of Figure 1. Intravenous iron dosing interval changes for the study patients (n ¼ 40). 2 DIALYSIS & TRANSPLANTATION SEPTEMBER 2006
3 Table I. Study period IV iron dosing interval changes during the study period for Group I (n ¼ 8) and Group II (n ¼ 32).* 1st Quarter 2nd Quarter 3rd Quarter Action Group 1 Group 2 Group 1 Group 2 Group 1 Group 2 no change 2 (25%) 13 (40.6%) 2 (25%) 11 (34.4%) 2 (25%) 10 (31.3%) discontinued 3 (37.5%) 15 (46.9%) 4 (50%) 17 (53%) 4 (50%) 18 (56%) fecreased interval 2 (25%) 1 (3%) 1 (12.5%) 1 (3%) 1 (12.5%) 1 (3%) increased interval 1 (12.5%) 3 (10%) 1 (12.5%) 3 (10%) 1 (12.5%) 3 (10%) *Group I originally received 100 mg IV iron every other week; Group II originally received 100 mg IV iron every fourth week. 100 mg of iron sucrose every other week or every fourth week achieved higher ferritin and TSAT levels than those set as goals by the Anemia Work Group. Sixty-two percent of our patients required an adjustment in their dosage, and more than 50% either discontinued therapy or required a reduction in dose after 1 quarter. This dose may represent an excess iron requirement in adult HD patients. One study estimated an average iron loss of 28 mg per week, and therefore determined the maintenance dose of IV iron gluconate to be mg per week. The authors concluded that mg of iron per week could not prevent the risk of iron overload. 5 Another observational study used the administration of 100 mg of iron sucrose once weekly to maintain a target ferritin level of ng/ml, and a TSAT of 30% 45%. In this study, more than 50% of the patients achieved a ferritin level >1,100 ng/ml. 6 In the present study, 100 mg of IV iron sucrose was administered every other week or every fourth week to adult chronic HD patients to maintain ferritin levels of ng/ml and TSAT levels of 20% 45%. This resulted in more than 50% of patients exceeding the target levels. The upper ferritin and TSAT targets were chosen to reduce the probability that the iron parameters would exceed the NKF-K/DOQI recommendations of 800 ng/ml ferritin and 50% TSAT. Administering too much iron may lead to excess iron and eventually to the development of iron overload. 7 It is important to monitor and assess iron parameters frequently in order to minimize any potential risks of iron overload. For the most part, IV iron therapy has been proven safe and effective, but the long-term risks such as its effect on the cardiovascular system and infection are still debated. A previous study suggested elevated serum ferritin levels were associated with an increased risk of myocardial infarction, and other studies raised questions about the relationship between oxidative stress and cardiovascular tissue damage. 8 9 Several previous articles pointed out the association between IV iron and infection. It was reasoned that infection was a result of IV iron stimulating bacterial growth and increasing the replication of bacteria during an infectious process Collins et al. reported that among Medicare recipients with higher claims, iron usage for at least 4 months was associated with increased infectionrelated deaths. 12 The amount of iron administered to HD patients to replace iron loss varies considerably, as can be seen in the results of the present study. The average reported iron loss among HD patients is about 2 g per year, but can reach approximately 3 g per year. 1,3,13 Among the 40 chronic dialysis patients in this study, 8 (20%) were receiving every-otherweek dosing, and 32 (80%) were receiving every-fourth-week dosing. After 1 quarter 75% of the patients on the every-other-week regimen and more than 50% of the patients on the every-fourth-week regimen had their regimen changed. The numbers constantly changed throughout the three quarters, and by the end of the third quarter, close to 70% of those initially on the every-fourth-week regimen had had their regimen changed, with only about 30% of the patients remaining on the original regimen. This variation is probably a result of the severity and chronic nature of the disease affecting dialysis patients. It is often difficult to predict the exact amount of iron required for the hemodialysis patient population, as many patients have multiple comorbid diseases and concurrent conditions such as gastrointestinal bleeding, infection, inflammation, variation in the amount of nutrient intake, and concurrent erythropoietic therapy. Iron sucrose (100 mg) was administered every other week to maintain ferritin levels of at least 100 ng/ ml but less than 500 ng/ml and TSAT of 20% 30% and every fourth SEPTEMBER 2006 DIALYSIS & TRANSPLANTATION 3
4 Rico, and the U.S. Virgin Islands, is 1 of 18 ESRD Network in the United States. Its goal is to collect data and to oversee ESRD care for all dialysis patients. It is close to impossible to have 100% of HD patients achieve the desired hemoglobin levels because their failed kidneys do not produce erythropoietin hormone, which is not present to stimulate the bone marrow to produce more red blood cells. Also making it nearly impossible for dialysis patients to achieve desired hemoglobin levels is that many are very sick, have multiple chronic conditions, have phlebotomies for blood work done on a regular basis, and lose blood every time they are dialyzed. Iron measurements were reported based solely on serum ferritin and transferrin saturation levels without consideration of other factors such as blood loss, acute illness, or other comorbid conditions. The small number of patients who required a dose increase did not affect the overwhelmingly high ferritin and TSAT levels. It is essential to establish comprehensive iron guidelines and to closely monitor iron therapy and hematologic response parameters in order to maximize the benefit of IV iron administration in this practice setting. The amount of iron administered to HD patients varies considerably. It is often difficult to predict the exact amount required for these patients, as many have multiple comorbid diseases and concurrent conditions. week to maintain ferritin levels ng/ml or TSAT of 30% 45%. This resulted in more than 50% of all the patients in the study having adjustments made to their regimens, either discontinuation of therapy or a decrease in dosing interval after the first quarter, and up to 55% of the patients having their regimens discontinued or their dosing interval decreased by the end of the third quarter. Given that a small percentage of patients remained on the same regimen based on the predefined criteria throughout the entire evaluation (3 quarters), it was concluded that adult HD patients may not need as much IV iron as previously anticipated, reflecting the K/DOQI recommendations. As a result, the protocol at the institution where the present study took place was re-evaluated, and necessary adjustments were made. The dose of IV iron sucrose was reduced from 100 mg to 60 mg. This dose seems to be a more appropriate iron replacement that better reflects the average iron loss of dialysis patients. 5 On average, 80% of the patients maintained the target hemoglobin level of g/dl recommended by the K/DOQI guidelines. The goal was to have as many patients as possible maintain this target. Meeting the anemia management goals of the Trans-Atlantic Renal Council Network was another objective. The goal was for 80% of pre-dialysis patients to maintain a hemoglobin level of at least 11 g/dl. 14 The Trans- Atlantic Renal Council Network, which consists of New Jersey, Puerto During the study, patients also received erythropoietic growth factor (darbepoetin alfa) to maintain target hemoglobin levels. The weekly average darbepoetin alfa dose was 55 (5) mg. To my knowledge, this is one of only a few studies that have also reported the average darbepoetin alfa dose in hemodialysis. Darbepoetin alfa is relatively newer than epoetin alfa and therefore is less extensively used or reported in the literature for this patient population. It would have been interesting to observe the trend of IV iron and its effects on darbepoetin alfa usage, but it was not the intention of this study and hence no comparison data were evaluated, although IV iron therapy has been shown to reduce erythropoietic usage and at the same time help to maintain desired hemoglobin levels. 15,16 Limitations to the present study include the lack of a control group. Conclusions Administration of supplemental IV iron to end-stage renal disease patients has been proven to be beneficial in managing anemia. With a regimen of 100 mg of iron sucrose administered intravenousely every other week or every fourth week, the iron requirements for most adult HD patients were exceeded in terms of the serum ferritin and TSAT levels suggested by the NKF-K/DOQI guidelines. This article was presented as an abstract (No. 202E) at the American College of Clinical Pharmacy Annual Meeting, San Francisco, California, October 23 26, The author acknowledges Danielle Picone, BSN, RN, CNN, and Jennifer Ash, PharmD, for reviewing the manuscript. Statistical analysis was done by Kailin Tu, director, Performance Engineering. References 1. Eschbach JW, Cook JD, Scribner BH, et al. Iron balance in hemodialysis patients. Ann Intern Med. 1977;87: DIALYSIS & TRANSPLANTATION SEPTEMBER 2006
5 2. Fishbane S, Wagner J. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. Am J Kidney Dis. 2001;37: NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease. Am J Kidney Dis 2001;37(Suppl 1):S194 S Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50: Canaves C, Bergamo D, Ciccone G, et al. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferring levels in chronic hemodialysis patients. Nephrol Dial Transplant. 2004;19: Edwards JH. Clinical review of the newer intravenous iron therapy options. Nephrol Nurs J. 2003;30(1): Venofer. Package insert. Shirley, NY: American Regent Laboratories, Inc., Morrison HI, Semenciw RM, Mao Y, et al. Serum iron and risk of fatal acute myocardial infarction. Epidemiology. 1994;5: Besarab A, Frinak S, Yee J. An indistinct balance: the safety and efficacy of parenteral iron therapy. J Am Soc Nephrol. 1999;10: Hoen B. Iron and infection: clinical experience. Am J Kidney Dis. 1999;34(Suppl 2):S30 S Douvas GS, May MH, Pearson JR, et al. Hypertriglyceridemia, very low density lipoprotein and iron enhance mycobacterium avium replication in human macrophages. J Infect Dis. 1994;170: Collins A, Ebben J, Ma J. Frequent IV iron dosing is associated with higher infectious deaths [abstract]. J Am Soc Nephrol. 1997; 8:190A. Abstract A Cook JD, Eschbach JW. Iron absorption and loss in CKD. In: Iron Metabolism and Its Disorders. Excerpta Medica International Congress Series 366. New York: Elsevier, 1975: Available at: Accessed April 19, Chang CK, Chang CC, Chang SS. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol. 2002;57: Richardson D, Bartlett C, Will EJ. Optimizing erythropoietin therapy in hemodialysis patients. Am J Kid Dis. 2001;38: SEPTEMBER 2006 DIALYSIS & TRANSPLANTATION 5
Aranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?
ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia
More informationNew Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients
23. Berliner DialyseSeminar 1.-4. Dezember 2010 New Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients George R. Aronoff, MD, MS, FACP Professor of Medicine and
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationNURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL EDUCATIONAL PACKAGE TABLE OF CONTENTS:
CANN-NET ANEMIA MANAGEMENT FOR HEMODIALYSIS CENTRES NURSE OR PHARMACIST-LED ANEMIA MANAGEMENT TABLE OF CONTENTS: PROTOCOL EDUCATIONAL PACKAGE Page 2: CANN-NET Anemia Management Protocol: Educational Document
More informationHemodialysis patients with endstage
Insights into Achieving Target Hemoglobin Levels: Increasing the Serum Ferritin Parameter Scott Bralow, DO Dr. Scott Bralow is the Medical Director of the Renal Center of Philadelphia. Evidence suggests
More informationIntravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University
Intravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University Use of IV Iron There are increasing data regarding safety of IV iron. IV iron is superior to
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationTSAT PROJECT Shean Strong, QI Director Lisle Mukai, QI Coordinator
Southern California Renal Disease Council, Inc. ESRD Network 18 TSAT PROJECT Shean Strong, QI Director Lisle Mukai, QI Coordinator TSAT 6255 West Sunset blvd Los Angeles, California i 90028 11/24/2010
More informationThe safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients
Kidney International, Vol. 68 (2005), pp. 1801 1807 The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients BRUCE S. SPINOWITZ, MICHAEL H. SCHWENK, PAULA M. JACOBS, W.
More informationThe safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease
Kidney International, Vol. 64, Supplement 87 (2003), pp. S72 S77 The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease DANIEL A. BLAUSTEIN, MICHAEL
More informationFuture Direction of Anemia Management in ESRD. Jay B. Wish, MD 2008 Nephrology Update March 20, 2008
Future Direction of Anemia Management in ESRD Jay B. Wish, MD 2008 Nephrology Update March 20, 2008 The Evidence Normal Hct Study and CHOIR demonstrate adverse outcomes in ESA patients with target Hgb
More informationModerators: Heather A. Nyman, Pharm.D., BCPS Clinical Pharmacist, Dialysis, University of Utah Dialysis Program, Salt Lake City, Utah
Immunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient Activity No. 0217-0000-11-076-L01-P (Knowledge-Based Activity) Monday, October 17 1:30
More informationAnemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN
Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition
More informationComment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease.
Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Goldsmith D, Blackman A, Gabbay F, June 2013 Kidney Disease: Improving Global Outcomes (KDIGO)
More informationDrugs Used in Anemia
Drugs Used in Anemia Drugs of Anemia Anemia is defined as a below-normal plasma hemoglobin concentration resulting from: a decreased number of circulating red blood cells or an abnormally low total hemoglobin
More informationPublished Online 2013 July 24. Research Article
Nephro-Urology Monthly. 2013 September; 5(4):913-7. Published Online 2013 July 24. DOI: 10.5812/numonthly.12038 Research Article Comparative Study of Intravenous Iron Versus Intravenous Ascorbic Acid for
More informationImmunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient
Immunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient Activity No. 0217-0000-11-076-L01-P Monday, October 17 1:30 p.m. 3:30 p.m. Convention
More informationAETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA)
AETNA BETTER HEALTH Prior Authorization guideline for Erythropoiesis Stimulating Agents (ESA) Drugs Covered Procrit Epogen Aranesp Authorization guidelines For patients who meet all of the following: Does
More informationMaintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F
Maintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationIron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia
Iron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia Paolo Pedrazzoli, MD 1, Giovanni Rosti, MD 2, Simona Secondino, MD 1, and Salvatore Siena, MD 1 Unresponsiveness
More informationManagement of anemia in CKD
Management of anemia in CKD Pierre Cochat, MD PhD Professor of Pediatrics Chair, Pediatrics & Pediatric Surgery Department Head, Center for Rare Renal Diseases Néphrogones Hospices Civils de Lyon & University
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationNo Disclosures 03/20/2019. Learning Objectives. Renal Anemia: The Basics
Renal Anemia: The Basics Meredith Atkinson, M.D., M.H.S. Associate Professor of Pediatrics Johns Hopkins School of Medicine 16 March 2019 No Disclosures Learning Objectives At the end of this session the
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd
Resubmission ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd 06 May 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationClinical Policy: Iron Sucrose (Venofer) Reference Number: CP.PHAR.167
Clinical Policy: (Venofer) Reference Number: CP.PHAR.167 Effective Date: 03/16 Last Review Date: 03/17 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory
More informationIron metabolism anemia and beyond. Jacek Lange Perm, 8 October 2016
Iron metabolism anemia and beyond Jacek Lange Perm, 8 October 2016 1 Overview 1. Iron metabolism 2. CKD Chronic Kidney Disease 3. Iron deficiency beyond anemia and CKD 4. Conclusions 2 Why iron deficiency
More informationEffective Health Care Program
Comparative Effectiveness Review Number 83 Effective Health Care Program Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease Executive Summary Background Chronic
More informationChanges in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin
http://www.kidney-international.org & 11 International Society of Nephrology see commentary on page 265 Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate
More informationTitle: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review
Title: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review Date: 14 February 2008 Context and policy issues: Anemia is a complication of chronic diseases and commonly occurs in
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Venofer) Reference Number: CP.PHAR.167 Effective Date: 07.01.18 Last Review Date: 02.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important Reminder at
More informationInjectable Iron Products
Injectable Iron Products Allyson Gabbard, Pharm.D. PGY1 Pharmacy Specialist Resident INTEGRIS Baptist Medical Center 1 Learning Objectives Compare and contrast the different injectable iron products. List
More informationNURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL
CANN-NET ANEMIA MANAGEMENT FOR HEMODIALYSIS CENTRES NURSE OR PHARMACIST-LED ANEMIA MANAGEMENT PROTOCOL TABLE OF CONTENTS: Hemoglobin Status Assessment ------------------------------------------- Page 1
More informationSYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA
SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,
More informationFDA Advisory Committee Briefing Document
FDA Advisory Committee Briefing Document Drug Safety and Risk Management Committee February 1, 2008 Prepared by the Division of Medical Imaging and Hematology Products/Office of Oncology Drug Products/Office
More informationStages of chronic kidney disease
For mass reproduction, content licensing and permissions contact Dowden Health Media. Jonathan J. Taliercio, DO Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio talierj@ccf.org
More informationThe Changing Clinical Landscape of Anemia Management in Patients With CKD: An Update From San Diego Presentation 1
Presentation 1 The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants
More informationEffective Health Care
Number 3 Effective Health Care Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Executive Summary Background Anemia (deficiency of red blood
More informationAnemia Update. Target Hb TREAT study Functional iron deficiency - Hepcidin Biosimilar epoetins
Anemia Update Peter Bárány Department of Renal Medicine/ Karolinska University Hospital and Division of Renal Medicine Department of Clinical Science, Intervention and Technology Karolinska Institutet,
More informationmean hemoglobin 11 g/dl (110 g/l) compared to patients with lower mean hemoglobin values (Table 20).
S44 Figure 53 depicts the trend in Epoetin dosing from the 1998 study period to the 2003 study period, with an increasing mean weekly Epoetin dose (units/kg/wk) for patients prescribed Epoetin in lower
More informationErythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS *
Erythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS * DESCRIPTION Erythropoietin is a glycoprotein produced in the kidneys responsible for the stimulation of red blood cell production. Epoetin
More informationOriginal Article Anemia management trends in patients on peritoneal dialysis in the past 10 years
Int J Clin Exp Med 2015;8(10):18050-18057 www.ijcem.com /ISSN:1940-5901/IJCEM0011104 Original Article Anemia management trends in patients on peritoneal dialysis in the past 10 years Huaye Liu, Yao Yao,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Methoxy polyethylene glycol-epoetin beta (Mircera) Reference Number: CP.CPA.322 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationDrug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs)
Drug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs) Line of Business: Medicaid P & T Approval Date: May 16, 2018 Effective Date: July 1, 2018 This policy has been developed
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals
ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationORIGINAL ARTICLE. Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease
32 Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease N Nand 1, S Venu 2, AR Deshmukh 2, R Mittal 2 ORIGINAL ARTICLE Abstract This study
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationMedication Prior Authorization Form
Procrit, Aranesp and (Epoetin Alfa) Policy Number: 1043 Policy History Approve Date: 12/11/2015 Effective Date: 12/11/2015 Preauthorization All Plans Benefit plans vary in coverage and some plans may not
More informationErythropoiesis Stimulating Agents (ESA)
Erythropoiesis Stimulating Agents (ESA) Policy Number: Original Effective Date: MM.04.008 04/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription
More informationLiterature Scan: Erythropoiesis Stimulating Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Darbepoetin Alfa (Aranesp) Reference Number: CP.PHAR.236 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important
More informationIron Status in Chronic Renal Failure with Anemia
Chattagram Maa-O-Shishu Hospital Medical College Journal DOI: 10.11566/cmosh.2013.1201.12 Original Article Iron Status in Chronic Renal Failure with Anemia Shaheda Khanam 1 * Noorzahan Begum 2 AMM Ehteshamul
More informationYoung Ki Lee, Sung Gyun Kim, Jang Won Seo, Ji Eun Oh, Jong-Woo Yoon, Ja-Ryong Koo, Hyung Jik Kim and Jung Woo Noh
Nephrol Dial Transplant (2008) 23: 3240 3246 doi: 10.1093/ndt/gfn255 Advance Access publication 9 May 2008 Original Article A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection
More informationORIGINAL PAPER. Introduction
ORIGINAL PAPER Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study F. Dellanna, 1
More informationClinical Policy: Ferumoxytol (Feraheme) Reference Number: CP.PHAR.165
Clinical Policy: (Feraheme) Reference Number: CP.PHAR.165 Effective Date: 03/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationK atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006
K atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006 Why new guidelines? Rationale for KDOQI Anemia 2006 Expand scope to all
More informationEPO e Ferro in Emodialisi: Il PBM al suo esordio. Lucia Del Vecchio. Divisione di Nefrologia e Dialisi Ospedale A. Manzoni, ASST Lecco
PATIENT BLOOD MANAGEMENT DALLA TEORIA ALLA PRATICA 16 FEBBRAIO 2018 EPO e Ferro in Emodialisi: Il PBM al suo esordio Lucia Del Vecchio Divisione di Nefrologia e Dialisi Ospedale A. Manzoni, ASST Lecco
More informationAppropriateness of anemia management in hemodialysis patients
Saudi Pharmaceutical Journal (2012) 20, 85 91 King Saud University Saudi Pharmaceutical Journal www.ksu.edu.sa www.sciencedirect.com PRACTICE REPORT Appropriateness of anemia management in hemodialysis
More informationOptimization of Epoetin Therapy with Intravenous Iron Therapy in Hemodialysis Patients
J Am Soc Nephrol 11: 530 538, 2000 Optimization of Epoetin Therapy with Intravenous Iron Therapy in Hemodialysis Patients ANATOLE BESARAB,* NEETA AMIN, MUHAMMAD AHSAN,* SUSAN E. VOGEL,* GARY ZAZUWA,* STANLEY
More informationIron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Shaikh Zayed Hospital, Lahore
Proceeding S.Z.P.G.M.I. Vol: 29(2): pp. 83-87, 2015. Iron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Waqar Ahmad, Muhammad Rizwan Ul Haque, Abad Ur Rehman and Sammiullah
More informationDose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
Adv Ther (2013) 30:1007 1017 DOI 10.1007/s25-013-0063-y ORIGINAL RESEARCH Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study Peter Choi Mourad
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Policy: Darbepoetin alfa (Aranesp) Reference Number: ERX.SPMN.13
Clinical Policy: (Aranesp) Reference Number: ERX.SPMN.13 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationWilliam E. Strauss *, Naomi V. Dahl, Zhu Li, Gloria Lau and Lee F. Allen
Strauss et al. BMC Hematology (2016) 16:20 DOI 10.1186/s12878-016-0060-x RESEARCH ARTICLE Open Access Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients
More informationAnemia in ESRD patients is effectively treated by the
Randomized Trial of Model Predictive Control for Improved Anemia Management Michael E. Brier,* Adam E. Gaweda, Andrew Dailey, George R. Aroff, and Alfred A. Jacobs *Department of Veterans Affairs, Louisville,
More informationLow-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients
Nephrol Dial Transplant (2004) 19: 1564 1570 DOI: 10.1093/ndt/gfh136 Advance Access publication 5 March 2004 Original Article Low-dose continuous iron therapy leads to a positive iron balance and decreased
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (2000) 15 [Suppl 4]: 33 42 Nephrology Dialysis Transplantation European Best Practice Guidelines 9 13 Anaemia management Claude Jacobs, Walter H. Hörl, Iain C. Macdougall, Fernando
More informationIN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006
IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE
More informationObjectives. Current WHO Definition of Anemia. Implication for Clinical Practice 10/8/18. Prevalence of Iron Deficiency in Women Undergoing Surgery
Pre-operative Anemia Clinic Dr Mike Scott MB ChB FRCP FRCA FFICM Professor in Anesthesiology and Critical Care Medicine Divisional Lead for Critical Care Medicine VCU Health System, Richmond, VA Professor
More informationCurrent situation and future of renal anemia treatment. FRANCESCO LOCATELLI
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationIntercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients
Clinical Nephrology, Vol. 71 No. 4/2009 (397-404) Intercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients Original 2009 Dustri-Verlag Dr. K. Feistle ISSN
More informationPreoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD
Preoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD Preoperative anemia is common, especially in patients undergoing nonemergent high-blood-loss surgical
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationThe efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis
Nephrol Dial Transplant (2006) 21: 2846 2850 doi:10.1093/ndt/gfl387 Advance Access publication 5 August 2006 Original Article The efficacy of intravenous darbepoetin alfa administered once every 2 weeks
More informationOPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease
Nephrol Dial Transplant (2007) 22 [Suppl 3]: iii2 iii6 doi:10.1093/ndt/gfm014 OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease W. H. Ho rl 1, I. C. Macdougall 2, J.
More informationClinical Policy Title: Erythropoietin for end-stage renal disease
Clinical Policy Title: Erythropoietin for end-stage renal disease Clinical Policy Number: 00.02.07 Effective Date: June 1, 2015 Initial Review Date: February 19, 2014 Most Recent Review Date: January 18,
More informationAjay Gupta 1,2, Vivian Lin 2, Carrie Guss 2, Raymond Pratt 2, T. Alp Ikizler 3 and Anatole Besarab 4,5
http://www.kidney-international.org 25 International Society of Nephrology clinical trial OPEN see commentary on page 946 Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating
More informationA rationale for an individualized haemoglobin target
Nephrol Dial Transplant (2002) 17 [Suppl 6 ]: 2 7 A rationale for an individualized haemoglobin target Norman Muirhead University of Western Ontario, London, Ontario, Canada Abstract Despite the use of
More informationLong-term iron accumulation in dialysis patients treated with ferric citrate hydrate: a single-center, 80-week retrospective study in Japan
Hiratsuka et al. Renal Replacement Therapy (2017) 3:37 DOI 10.1186/s41100-017-0118-7 RESEARCH Open Access Long-term iron accumulation in dialysis patients treated with ferric citrate hydrate: a single-center,
More informationMaintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study
original article http://www.kidney-international.org & 2008 International Society of Nephrology Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a
More informationIS IV IRON SUCROSE SIMILAR SAFE FOR MY PATIENTS?
IS IV IRON SUCROSE SIMILAR SAFE FOR MY PATIENTS? Jeong Jae Lee, M.D., Ph.D. Department of Obstetrics and Gynecology Soonchunhyang University Hospital Seoul, Korea 1 Contents Introduction The role of intravenous
More informationInternationally indexed journal
www.ijpbs.net Internationally indexed journal Indexed in Chemical Abstract Services (USA), Index coppernicus, Ulrichs Directory of Periodicals, Google scholar, CABI,DOAJ, PSOAR, EBSCO, Open J gate, Proquest,
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence 2-year surveillance (2017) Chronic kidney disease: managing anaemia (2015) NICE guideline NG8 Appendix A3: Summary of new evidence from surveillance Diagnostic
More informationDarbepoetin alfa (Aranesp TM )inchildren with chronic renal failure
Kidney International, Vol. 68 (2005), pp. 1759 1765 Darbepoetin alfa (Aranesp TM )inchildren with chronic renal failure DENIS F. GEARY, LAURA E. KEATING, ANNETTE VIGNEUX, DEREK STEPHENS, DIANE HÉBERT,
More informationClinical Policy: Ferric Carboxymaltose (Injectafer) Reference Number: CP.PHAR.234
Clinical Policy: (Injectafer) Reference Number: CP.PHAR.234 Effective Date: 06/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationAnemia Management: Using Epo and Iron
Anemia Management: Using Epo and Iron Ky Stoltzfus, MD University of Kansas Medical Center Assistant Professor Department of Internal Medicine January 23, 2013 Regulation of red cell production Treatment
More informationVenofer (iron sucrose injection, USP)
Page 3 Venofer (iron sucrose injection, USP) Rx Only DESCRIPTION Venofer (iron sucrose injection, USP) is a brown, sterile, aqueous, complex of polynuclear iron (III)- hydroxide in sucrose for intravenous
More informationLife Science Journal 2013;10(4)
Short Term Low Dose Intravenous Ascorbic Acid in Functional Iron Deficiency Anemia in Hemodialysis Patients Magdy El-Sharkawy¹, Walid Bichari ¹, Mostafa Kamel ¹ and Hanaa Fathey ² ¹ Internal Medicine and
More informationStudy of Management of anemia in Chronic Kidney Disease Patients
Review Article Study of Management of anemia in Chronic Kidney Disease Patients Meby Susan Mathew, Nama Ravi Sneha Keerthi, Neelathahalli Kasturirangan Meera* Meera N.K, Visveswarapura Institute of Pharmaceutical
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More information7/22/2018. Team approach directed by the Department of Pharmacy for management of anemia and bone mineral disorder in chronic dialysis patients
Team approach directed by the Department of Pharmacy for manment of anemia and bone mineral disorder in chronic dialysis patients Disclosure Statement The authors of this presentation have research support
More informationYEAR III Pharm.D Dr. V. Chitra
YEAR III Pharm.D Dr. V. Chitra Anemia can be defined as a reduction in the hemoglobin,hematocrit or red cell number. In physiologic terms an anemia is any disorder in which the patient suffers from tissue
More informationApril 12, Coverage of ESAs for Patients with Conditions Other than End-Stage Renal Disease
[ASH Comments to the Centers for Medicare and Medicaid Services on coverage for Erythropoiesis Stimulating Agents (ESAs) filed electronically on April 12, 2007] April 12, 2007 The American Society of Hematology
More informationGuideline Summary NGC-6019
NGC banner Guideline Summary NGC-6019 Guideline Title (1) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. (2) 2007 update of hemoglobin target.
More informationAmong patients with peritoneal dialysis dependent
CJASN epress. Published on March 29, 2006 as doi: 10.2215/CJN.01541005 Effect of Intravenous Iron Sucrose in Peritoneal Dialysis Patients Who Receive Erythropoiesis-Stimulating Agents for Anemia: A Randomized,
More information